Page last updated: 2024-10-27

gabapentin and Vasculitis

gabapentin has been researched along with Vasculitis in 2 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Okon, T1
Kontogiannis, V1
Havlat, M1
Lowe, JS1
Powell, RJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Oral Ketamine for Control of Chronic Pain in Children[NCT01369680]Phase 112 participants (Actual)Interventional2011-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Neurocognitive Effect

"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks

Interventionparticipants (Number)
Ketamine 0.25 mg/kg/Dose0
Ketamine 0.5 mg/kg/Dose0
Ketamine 1 mg/kg/Dose0
Ketamine 1.5 mg/kg/Dose0

Norketamine Cmax (Measured in ng/mL).

Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1

Interventionng/mL (Mean)
Ketamine 0.25 mg/kg/Dose37.5
Ketamine 0.5 mg/kg/Dose135
Ketamine 1 mg/kg/Dose250

Number of Participants Tolerating Dose

According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks

Interventionparticipants (Number)
Ketamine 0.25 mg/kg/Dose3
Ketamine 0.5 mg/kg/Dose3
Ketamine 1 mg/kg/Dose3
Ketamine 1.5 mg/kg/Dose1

Pain Control

"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2

Interventionparticipants (Number)
Ketamine 0.25 mg/kg/Dose3
Ketamine 0.5 mg/kg/Dose0
Ketamine 1 mg/kg/Dose2
Ketamine 1.5 mg/kg/Dose0

Reviews

1 review available for gabapentin and Vasculitis

ArticleYear
Ketamine: an introduction for the pain and palliative medicine physician.
    Pain physician, 2007, Volume: 10, Issue:3

    Topics: Adult; Amines; Analgesics; Analgesics, Opioid; Central Nervous System; Cryoglobulinemia; Cyclohexane

2007

Other Studies

1 other study available for gabapentin and Vasculitis

ArticleYear
Lesson of the month: Systemic vasculitis or not? That is the question.
    Annals of the rheumatic diseases, 1999, Volume: 58, Issue:10

    Topics: Acetates; Amines; Anticoagulants; Anticonvulsants; Brain; Carbamazepine; Central Nervous System Dise

1999
chemdatabank.com